KYE Announces Commercial Availability of PrCORZYNATM (ranolazine 500 mg extended-release tablets)
MISSISSAUGA, ON, MAY 4, 2021 (CANADA NEWSWIRE)
KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, CORZYNA™ (ranolazine extended-release tablets) has now been made commercially available and is in wholesalers across Canada after a positive expedited review by Health Canada.
CORZYNA™ is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (including beta- blockers and calcium channel blockers). Ranolazine has been available internationally for well over a decade and is globally recognized in international treatment guidelines as an effective and safe add-on therapy for stable angina that is not well controlled with currently available agents.
“KYE is extremely pleased to announce that CORZYNA™, an important new class of antianginal medication, is now available in Canada” stated Doug Reynolds, President of KYE, “This is a step forward for Canadian patients and healthcare professionals in the treatment of stable angina as CORZYNA™ provides an additional option for those patients who are not being adequately managed with currently available first- line therapies and continue to experience recurrent angina episodes”.
About Stable Angina
Angina is the term for chest pain or chest discomfort. Angina occurs when the heart muscle is not getting enough blood and therefore enough oxygen to work properly. It is usually caused by hardening of the arteries. Chronic angina, the most common symptom of coronary artery disease, can be a debilitating heart condition. Angina typically manifests as recurrent pain or tightness in the chest upon exertion or emotional stress.
About KYE Pharmaceuticals
KYE Pharmaceuticals Inc. (KYE) is a private company headquartered in Mississauga, Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team’s strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, our patients. For more information, please visit www.kyepharma.com.
May 04, 2021 at 8:30 AM EDT